**Egypt**

**Population 2017** 98 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>0.41 (0.37–0.46)</td>
<td>0.42 (0.38–0.47)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.013 (&lt;0.01–0.021)</td>
<td>0.01 (0.01–0.02)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>13 (11–14)</td>
<td>13 (12–14)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.053 (0.034–0.076)</td>
<td>0.05 (0.04–0.08)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>2.2 (1.8–2.7)</td>
<td>2.3 (1.8–2.7)</td>
</tr>
</tbody>
</table>

**Estimated TB incidence by age and sex (thousands)*, 2017**

<table>
<thead>
<tr>
<th></th>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>0.63 (0.61–0.64)</td>
<td>4.5 (4.2–4.8)</td>
<td>5.2 (4.8–5.5)</td>
</tr>
<tr>
<td>Males</td>
<td>0.69 (0.68–0.71)</td>
<td>6.8 (6.3–7.4)</td>
<td>7.5 (6.9–8.2)</td>
</tr>
<tr>
<td>Total</td>
<td>1.3 (1.3–1.4)</td>
<td>11 (10–13)</td>
<td>13 (11–14)</td>
</tr>
</tbody>
</table>

**TB case notifications, 2017**

- Total cases notified: 8 195
- Total new and relapse: 8 053
  - % tested with rapid diagnostics at time of diagnosis: 75%
  - % with known HIV status: 35%
  - % pulmonary: 54%
  - % bacteriologically confirmed among pulmonary: 83%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2017: 63% (57–71)
- TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.03 (0.03–0.04)

**TB/HIV care in new and relapse TB patients, 2017**

- Patients with known HIV-status who are HIV-positive: 53% 2%
  - on antiretroviral therapy: 53 100%

**Drug-resistant TB care, 2017**

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 700 (600–800)
- Estimated % of TB cases with MDR/RR-TB: 14% (12–17) 30% (25–35)
- % notified tested for rifampicin resistance: 78% 95%
- MDTRR-TB cases tested for resistance to second-line drugs: 18
- Laboratory-confirmed cases: MDR/RR-TB: 152; XDR-TB: 0
- Patients started on treatment ****: MDR/RR-TB: 125; XDR-TB: 0

**Treatment success rate and cohort size**

- New and relapse cases registered in 2016: 87% 7 974
- Previously treated cases, excluding relapse, registered in 2016: 60% 309
- HIV-positive TB cases registered in 2016: 63% 16
- MDR/RR-TB cases started on second-line treatment in 2015: 65% 107
- XDR-TB cases started on second-line treatment in 2015: 0

**TB preventive treatment, 2017**

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 27% (25–30)

**TB financing, 2018**

- National TB budget (US$ millions)

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2018-11-18

Data: www.who.int/tb/data